Press Releases

Press Releases

October 1, 2019
WOBURN, Mass. , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Robert Coffin , Ph.D., Chief Executive Officer and Director of Replimune , will
August 6, 2019
WOBURN, Mass. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Philip Astley-Sparke , Executive Chairman and Director of Replimune , will present
May 30, 2019
WOBURN, Mass. , May 30, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members of its senior management team, will present and host investor meetings at the
Displaying 1 - 10 of 13